in Shandong Province, China were investigated using data collected from January 2002 to December 2006. A total of 10 337 isolates were characterized in sputum samples from 39 920 LRTI patients: 68.72% were Gram-negative bacteria, 20.65% were Gram-positive bacteria, and 10.62% were fungi. Organisms most frequently isolated were: Pseudomonas aeruginosa (16.88%), Klebsiella pneumoniae (10.80%), Escherichia coli (10.71%), fungi (10.62%), Staphylococcus aureus (9.68%) and Acinetobacter baumannii (9.03%).
Introduction
Lower respiratory tract infections (LRTIs) treated in hospital include severe cases of acute exacerbations of chronic bronchitis (AECB) and community-acquired pneumonia (CAP) as well as hospitalacquired pneumonia (HAP); the latter consists of ventilator-associated pneumonia (VAP) and healthcare-associated pneumonia (HCAP). 1 LRTIs are a common group of diseases encountered in hospital. For example, HAP is the second most common *Y Wang and R Zhang contributed equally to this work.
Y Wang, R Zhang, W Li et al. Serious antimicrobial resistance status in China nosocomial infection (NI) and accounts for approximately one-quarter of all infections in the intensive care unit (ICU) 2 One surveillance report of NI in China documented that LRTIs, which accounted for 31.5% of NI cases in 193 hospitals, were the leading cause of NIs. 3 As well as high mortality rates, LRTIs also pose a socioeconomic problem. For example, in the USA, the direct costs of LRTIs such as AECB have been estimated as US$1.2 billion for patients aged ≥ 65 years and US$419 million for patients < 65 years. 4, 5 Severe problems are also encountered in China although there are no data about the socioeconomic costs.
Inappropriate antibiotic therapy may increase a patient's stay in the hospital and predispose them to increased antibiotic resistance. 6 A direct correlation exists between antibiotic resistance and patient outcomes, including mortality, length of hospital stay and healthcare costs. 7, 8 There is, therefore, a great need for surveillance of antimicrobial resistance not only to provide early warning of emerging problematic resistances, but also to contribute towards designing appropriate strategies to manage antibiotic resistance. Appropriate surveillance has been highlighted as a key area to address in order to implement rational measures to tackle the antibiotic resistance problem worldwide. 9 Although microbiological investigations do not influence the clinical outcome and the routine use of antibiotics, they do have epidemiological value in providing local data on antibiotic resistance and seasonal variation in pathogen prevalence.
The present study analysed the NI surveillance data from Shandong Providence, which is a large province in north China and home to > 90 million people, to determine if there were any significant resistance patterns and trends that might help to improve the efficacy of empirical antibiotic therapy. 
Patients and methods

DATA COLLECTION
STATISTICAL ANALYSIS
Linear regression analysis was used to analyse resistance rate trends over time among pathogens causing LRTIs. Analysis of trends in annual resistance rates to each antimicrobial agent for each microorganism were performed using Durbin-Watson statistics. An r-value > 0.72 and a P-value < 0.05 were considered statistically significant. 11
Results
ISOLATES FROM LRTIs
A total of 10 337 isolates were characterized in sputum samples from 39 920 patients with 
ANTIMICROBIAL SUSCEPTIBILITY OF THE PATHOGENIC BACTERIA
Results of the antimicrobial resistance tests are shown in Tables 1 and 2 for Gramnegative and Gram-positive bacteria, respectively. Since there were only limited resistance data for fungi, only the 10 most frequently isolated bacterial species are included.
Resistance of Gram-negative bacteria
With regard to Gram-negative bacteria, imipenem was the most effective antibiotic, with antimicrobial resistance rates varying from 4.4% for E. coli to 19.4% for P. aeruginosa, with a mean resistance rate of 11.1% (Table 1) . Overall, ampicillin and cephazoline had the highest resistance rates of all of the Gram-negative bacteria tested, with means of 90.7% and 82.5% respectively.
When considering individual Gramnegative bacteria, P. aeruginosa had a resistance rate of 19.4% against the β-lactam antibiotic, imipenem, which was the most effective antibiotic against this species; followed by the cephalosporins ceftazidime and cefoperazone, with resistance rates of 28.1% and 33.7%, respectively (Table 1) . However, P. aeruginosa had a relatively high resistance (70.2%) against the other cephalosporin, cefotaxime, and > 40% of P. aeruginosa isolates were resistant to both fluoroquinolones (ciprofloxacin and ofloxacin). The antimicrobial resistance of K. pneumoniae to the β-lactam antibiotics was fairly high (> 50.0%), with the exception of cefotaxime (47.0%) and imipenem (5.1%). K. pneumoniae was also relatively resistant to amikacin (47.7%) and both fluoroquinolones (45.6% -53.7%). Only 4.4% of E. coli isolates were resistant to imipenem. Resistance rates of the E. coli isolates to the βlactam antibiotics were similar to those of P. aeruginosa, with the exception of cefotaxime, for which they had a relatively low resistance rate of 35.6%. The fluoroquinolones were less effective against E. coli, with resistance rates > 60% (ciprofloxacin 71.8%, ofloxacin 63.8%).
Resistance of Gram-positive bacteria
With regard to Gram-positive bacteria, vancomycin was extremely effective against the three most common bacteria: no vancomycin-resistant isolates of S. aureus and S. epidermidis were found and only 8.8% of S. pneumoniae isolates were resistant to vancomycin ( Table 2) .
When considering individual Grampositive bacteria, the antimicrobial resistance rates of S. aureus and S. epidermidis to vancomycin, amikacin, imipenem, and erythromycin were < 50%. Antimicrobial resistance against the fluoroquinolones ranged from 46.1% to 59.4% and against the cephalosporins resistance rates were > 42.5%. The resistance rates of S. aureus and S. epidermidis were greatest against penicillin Y Wang, R Zhang, W Li et al. 
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TRENDS IN ANTIMICROBIAL RESISTANCE OVER 5 YEARS
In general, the resistance profiles against the antibiotics increased during the 5 years of the study (2002 -2006) and Table 3 shows the trends among six of the most common pathogens: P. aeruginosa, K. pneumoniae, E. coli, A. baumannii, S. aureus and S. epidermidis. A significant increase in the resistance rate with time (r > 0.72 and P < 0.05) was found for ceftazidime-, amikacin-and ofloxacinresistant P. aeruginosa, ceftazidime-, imipenem-, amikacin-and ofloxacinresistant E. coli, and ofloxacin-resistant S. epidermidis.
Discussion
Patterns in the development of antimicrobial resistance among pathogens from hospitalized patients with LRTIs in Shandong Province, China between 2002 and 2006 were assessed in the present study. The percentages of antibiotic resistant isolates were found to be fairly high, with the exception of imipenem and vancomycin, which were the most effective antibiotics.
The proportion of Gram-negative bacteria causing LRTIs was 68.72%, which was similar to the 63.9% -68.4% of a report from Germany, 12 and this percentage appears to be increasing. The present study, found 13 but different from another report from Japan, 14 in which H. influenzae was the most common Gramnegative bacteria. In particular, the classical pathogens of LRTIs, H. influenzae and S. pneumoniae, accounted for only 3% of total isolates. This result was similar to a previous report from Latin America, 15 but differs from most other reports, 13, 14, 16 The present data showed that imipenem was the most effective antibiotic agent against Gram-negative bacteria, with a mean resistance of 11.1%, and higher than those of most Gram-negative bacilli found in the ICU. 17 P. aeruginosa was remarkably resistant to imipenem (19.4%). Dorobȃţ et al. 16 reported even higher resistance levels to imipenem and meropenem (28.2% and 26.0%, respectively) in LRTI patients. One possible reason is that P. aeruginosa appears to be the leading aetiological organism in ICU and burns units. 18 In addition, ceftazidime and cefoperazone were relatively active with resistance rates for P. aeruginosa of 28.1% and 33.7%, respectively. Dorobȃţ et al., 16 
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P. aeruginosa, ranging from 7.9% against amikacin to 38.3% against cefoperazone. The current resistance status of P. aeruginosa is of concern to clinicians.
In the present study, imipenem was effective against E. coli, with a low resistance rate of just 4.4%. In contrast, second and third generation cephalosporins were found to be less active, with moderate resistance rates ranging from 35.6% to 56.8%. In addition, amikacin was a candidate antimicrobial agent because E. coli isolates had a resistance rate of 34.3%. Resistance of E. coli to both fluoroquinolones was found to be high in the present study.
Antimicrobial resistance of the Gramnegative bacteria against both fluoroquinolones tested in the present study ranged from 30.0% to 73.8%, which gives cause for concern. Some reports delineate a role for fluoroquinolones for both non-ICU and ICU patients, either as first-line monotherapy or as part of combination therapy. 1 Despite 20 years of clinical use, fluoroquinolones are still active against 98% of S. pneumoniae strains in the USA, including penicillin-resistant strains. 19 Previous reports demonstrated that higher hospital-level use of fluoroquinolones was associated with an increased proportion of ciprofloxacin resistance among P. aeruginosa isolates causing hospital-acquired infections. 11 Quinolones are widely used in animal husbandry and some quinoloneresistant bacteria have inevitably appeared, which might transfer along the food chain and aggravate antimicrobial resistance in humans. 20 The widespread cumulative use of quinolones may be accelerating the development of antimicrobial resistance to these agents and may be the driving force behind increases in resistance. 21 In the present study, 20.65% of all the isolates recovered from LRTIs were Gram-positive bacteria, which is less than that reported by other studies, 14, 15 with S. aureus (9.68%) the most common. In North America, S. aureus is the most common pathogen causing pneumonia and was shown to account for 28.0% of isolates. 22 Glycopeptide antibiotics are the optimal choice for coccoid bacteria, particularly methicillin-resistant S. aureus (MRSA), and vancomycin used to be consistently effective against
Gram-positive bacteria. 23 Nevertheless, several vancomycin-resistant S. aureus have been isolated, all in patients with underlying conditions, including chronic skin ulcers, and most had received vancomycin prior to their vancomycinresistant infection. 24 The resistance rates of S. aureus and S. epidermidis to the antibiotics tested were similar in the present study, imipenem, amikacin and vancomycin being the most effective. Our data showed high levels of resistance to the β-lactam antibiotics with S. aureus and S. epidermidis, but not with S. pneumoniae. No isolates of S. pneumoniae were resistant to cefotaxime, 20% were resistant to cephazoline and the resistance rates against penicillin and ampicillin were around 50%.
The antimicrobial resistance trends were different for Gram-negative and Grampositive bacteria in the present study. There were significant increases in the antimicrobial resistance with most Gramnegative bacteria over time. The resistance rates of P. aeruginosa against ceftazidime, amikacin and ofloxacin, and of E. coli against ceftazidime, imipenem, amikacin and ofloxacin increased significantly during the 5 years studied. With regard to Grampositive bacteria, however, only ofloxacinresistant isolates of S. epidermidis increased significantly. In general, the antimicrobial resistance of Gram-negative bacteria increased and became quite high by 2006. In contrast, the most effective agents, vancomycin and some of the β-lactam antibiotics, maintained stable rates of antimicrobial resistance throughout the study period.
Our investigation of microbial isolates of presumed hospital-acquired LRTI pathogens showed that Gram-negative bacteria were the predominant pathogens and that antimicrobial resistance is severe in Shandong, China, which may be related to illegitimate antibiotic use. The treatment of patients with bacterial LRTIs is, therefore, becoming more complicated. In particular, the emergence of resistance to commonly prescribed antimicrobial agents by respiratory tract pathogens has compounded the problem. These results highlight the need for systematic interventions to ensure more consistent application of recommended guidelines for antimicrobial use. This 5-year study demonstrated that antimicrobial resistance of pathogens isolated from lower respiratory tracts has become a serious problem with some antibiotics, that the situation appears to be worsening annually and this creates selective pressure on physicians to use certain antibiotics.
Conflicts of interest
The authors had no conflicts of interest to declare in relation to this article.
